NCT04115059 2024-03-21
Dasatinib In Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1 Terminated
Clinical Trials
10 trialsNCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02011945 2020-03-18
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT02819804 2020-02-11
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Northwestern University
Phase 1 Terminated
NCT00882583 2019-01-09
Dasatinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00560352 2017-03-13
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Terminated
NCT00560391 2016-08-04
Dasatinib in Combination With Revlimid (and Dexamethasone)
Bristol-Myers Squibb
Phase 1 Completed
NCT00452673 2015-03-24
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Bristol-Myers Squibb
Phase 1 Completed
NCT00978731 2011-04-28
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
Bristol-Myers Squibb
Phase 1 Completed
NCT00339144 2010-12-15
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed